Corcept Therapeutics reported $109.36M in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Alaunos Therapeutics USD 2.49M 108K Jun/2026
ANI Pharmaceuticals USD 22.49M 760K Dec/2025
Ardelyx USD 249.15M 2.17M Jun/2026
Aurora Cannabis CAD 63.31M 4.36M Jun/2026
BioMarin Pharmaceutical USD 193.68M 141K Sep/2026
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Canopy Growth CAD 422.07M 53.78M Mar/2026
Corcept Therapeutics USD 109.36M 1.44M Sep/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
J&J USD 2.41B 1.64M Jun/2026
Knight Therapeutics CAD 99.68M 24.66K Sep/2025
Lexicon Pharmaceuticals USD 363.47M 67K Dec/2025
Merck USD 2.47B 1.05M Jun/2026
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Novartis USD 1.89B 12.09M Sep/2026
Novartis USD 1.89B 19.47M Sep/2026
Omeros USD 611K 17K Dec/2023
Pacira USD 39.9M 75K Sep/2026
Pfizer USD 5.7B 1000K Sep/2026
Supernus Pharmaceuticals USD 58.16M 124K Jun/2026
TG Therapeutics USD 151.16M 1.92M Sep/2026